DiaMedica Therapeutics Inc

(NASDAQ:DMAC)

Latest On DiaMedica Therapeutics Inc (DMAC):

Date/Time Type Description Signal Details
2023-05-16 12:52 ESTNewsDiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call TranscriptN/A
2023-03-29 11:42 ESTNewsDiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call TranscriptN/A
2023-03-28 21:07 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.52 in-lineN/A
2022-11-30 16:32 ESTNewsDiaMedica: What's Happened And What's The Value HereN/A
2022-11-09 23:13 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03N/A
2022-10-27 07:45 ESTNewsDiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trialN/A
2022-08-12 01:34 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 08:38 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.05N/A
2022-07-06 21:27 ESTNewsFDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical holdN/A
2022-05-16 11:12 ESTNewsDiaMedica Therapeutics Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-07 00:58 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-05 02:30 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07N/A
2022-03-15 22:19 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-15 02:31 ESTNewsDiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08N/A
2022-01-05 20:09 ESTNewsDiaMedica Therapeutics appoints chief medical officerN/A
2021-11-12 00:43 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-06 00:33 ESTNewsDiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.N/A
2021-09-30 13:30 ESTNewsDiaMedica gets FDA Fast Track status for acute ischemic stroke treatment DM199N/A
2021-09-27 16:22 ESTNewsDiaMedica Therapeutics to undertake $30M private equity offeringN/A
2021-09-21 16:39 ESTNewsDiaMedica Therapeutics (DMAC) Investor Presentation - SlideshowN/A
2021-08-12 15:59 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-11 19:36 ESTNewsDiaMedica Therapeutics EPS beats by $0.05N/A
2021-07-21 05:39 ESTNewsDiaMedica: Undercovered Stroke Drug Company With Decent DataN/A
2021-07-21 05:17 ESTNewsDiamedica shows mixed results for kidney disease therapy in mid-stage studyN/A
2021-07-21 04:53 ESTNewsDiaMedica Therapeutics adds two industry veterans to its board of directorsN/A
2021-05-06 10:44 ESTNewsDiaMedica Therapeutics reports Q1 resultsN/A
2021-03-18 12:32 ESTAnalyst RatingThe Analyst Target Price has increased from $20.67 to $22.17.Buy
2021-03-12 11:29 ESTAnalyst RatingThe Analyst Target Price has increased from $19.83 to $20.67.Buy
2021-03-12 02:43 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 15:30 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 11:29 ESTEarnings EstimateAn EPS average of -$1.19 is estimated for the 2022 year.Sell
2021-03-11 11:29 ESTEarnings EstimateAn EPS average of -$0.76 is estimated for the 2021 year.Sell
2021-03-11 11:29 ESTEarnings EstimateAn EPS average of -$0.19 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 06:01 ESTNewsDiaMedica Therapeutics EPS misses by $0.06N/A
2021-02-18 11:27 ESTAnalyst RatingThe Analyst Target Price has increased from $16.2 to $19.83.Buy
2021-01-05 11:39 ESTAnalyst RatingThe Analyst Target Price has increased from $13.4 to $16.2.Buy
2020-12-17 11:47 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021.Buy
2020-12-17 11:47 ESTEarnings EstimateAn EPS average of -$0.16 is estimated for the quarter ending on December 31, 2020.Buy
2020-12-17 11:47 ESTAnalyst RatingThe Analyst Target Price has increased from $0 to $13.4.Buy
2020-12-10 10:57 ESTNewsDiaMedica rises 6% on successful Type B meeting with FDA for DM199 study in acute ischemic strokeN/A
2020-11-26 19:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 19:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 07:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 05:35 ESTNewsDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 15:37 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 11:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 07:04 ESTNewsDiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call PresentationN/A
2020-11-05 03:04 ESTNewsDiaMedica Therapeutics EPS misses by $0.04N/A
2020-09-26 12:34 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:42 ESTFinancialsCompany financials have been released.Neutral

About DiaMedica Therapeutics Inc (DMAC):

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC Quotes by TradingView

See Advanced Chart

General

  • Name DiaMedica Therapeutics Inc
  • Symbol DMAC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Last Split Factor1:20
  • Last Split Date2018-11-15
  • Fiscal Year EndDecember
  • IPO Date2008-01-04
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.diamedica.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 7.28
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.79
  • Next Year EPS Estimate -$1.30
  • Next Quarter EPS Estimate -$0.19
  • Return on Assets -43%
  • Return on Equity -73%
  • Earnings Per Share -$0.90
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 180.81 million
  • EBITDA -9387000
  • Analyst Target Price $22.17
  • Book Value Per Share $1.39
View More

Share Statistics

  • Shares Outstanding 18.78 million
  • Shares Float 16.41 million
  • % Held by Insiders 672%
  • % Held by Institutions 39.31%
  • Shares Short 116640
  • Shares Short Prior Month 82969
  • Short Ratio 0.7
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 2.43
  • 52 Week High $10.88
  • 52 Week Low $1.87
  • 50 Day Moving Average 9.19
  • 200 Day Moving Average 6.69
View More

Dividends

  • Dividend Date 2018-11-15
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

DiaMedica Therapeutics Inc (DMAC) Dividend Calendar:

DMAC's last dividend payment was made to shareholders on November 15, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

DiaMedica Therapeutics Inc (DMAC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$N/A-$0.23-$0.16-41.54%
2020-09-302020-11-04$N/A-$0.19-$0.15-29.52%
2020-06-302020-08-11$N/A-$0.17-$0.14-25.93%
2020-03-312020-05-13$N/A-$0.19-$0.2933.33%
2019-12-312020-03-23$N/A-$0.21-$0.2516%
2019-09-302019-11-13$N/A-$0.20-$0.214.76%
2019-06-302019-08-13$N/A-$0.21-$0.2618.19%
2019-03-312019-05-13$N/A-$0.27-$0.20-35%
2018-12-312019-03-19$-3657-$0.11-$0.2657.69%
2018-09-302018-12-10$503657-$0.07
2018-06-302018-08-30$N/A-$0.46
2018-03-312018-04-30$N/A-$0.09
2017-09-302017-11-27$N/A-$0.15
2017-06-302017-08-29$N/A-$0.18
2017-03-312017-04-27$N/A-$0.24
2016-09-302016-11-29$N/A-$0.20
2016-06-302016-08-29$N/A-$0.12
2016-03-312016-04-29$N/A-$0.08
2015-09-302015-11-30$N/A-$0.07
2015-06-302015-08-31$N/A-$0.10
2015-03-312015-04-30$N/A-$0.14
2014-09-302014-11-28$N/A-$0.40-$0.20-100%
2014-06-302014-08-28$N/A-$0.40-$0.6033.33%
2014-03-312014-04-30$N/A-$0.40-$0.400%
2013-09-302013-11-28$N/A-$0.47
2013-06-302013-08-28$N/A-$0.80
2013-03-312013-03-31$N/A-$1.08
2012-12-312012-12-31$N/A-$1.25
2012-09-302012-09-30$N/A-$1.02

DiaMedica Therapeutics Inc (DMAC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 3.12 million 2.18 million N/A 1.38 million N/A
Income Before Tax -4.19 million -3.19 million N/A -2.42 million N/A
Selling General Administrative 1.15 million 1.14 million N/A 1.02 million 968000
Gross Profit N/A N/A N/A N/A N/A
Ebit -4.26 million -3.29 million N/A -2.28 million N/A
Operating Income -4.27 million -3.29 million N/A -2.29 million N/A
Income Tax Expense N/A N/A 9000 N/A 2000
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 75000 103000 N/A -127000 N/A
Net Income From Continuing Operations -4.2 million -3.19 million N/A -2.43 million N/A
Net Income Applicable to Common Shares N/A N/A -2.47 million N/A N/A
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -5.3 million N/A 3 million
Change to Liabilities 168000 108000 N/A N/A 50000
Total Cash Flow from Investing Activities -14 million 2.5 million N/A N/A 3 million
Net Borrowings -1000 -1000 N/A N/A -1000
Total Cash Flow from Financial Activities N/A N/A 7.7 million 70000 -1000
Change to Operating Activities 169000 411000 N/A N/A 381000
Change in Cash N/A N/A -583000 N/A 1.77 million
Total Cash from Operating Activities -2.35 million -844000 -2.98 million N/A -1.23 million
Depreciation N/A N/A 6000 21000 5000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A -162000 N/A 332000
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 520000 440000 N/A N/A 448000
Capital Expenditures N/A N/A 2000 N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 2.08 million 1.51 million N/A 1.04 million 1.44 million
Total Stockholder Equity 26.01 million 29.76 million N/A 13.32 million 7.62 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets 28.1 million 31.27 million N/A 14.37 million 9.05 million
Common Stock N/A N/A N/A N/A N/A
Other Current Assets N/A N/A N/A N/A 88000
Retained Earnings -68.91 million -64.71 million -61.52 million -59.04 million N/A
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash 7.41 million 9.8 million N/A 3.3 million N/A
Total Current Liabilities 2.03 million 1.44 million N/A 935000 1.32 million
Other Stockholder Equity N/A N/A 29000 N/A 2000
Property, Plant & Equipment N/A N/A 182000 N/A 217000
Total Current Assets 27.92 million 31.11 million N/A 14.17 million 8.84 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets N/A N/A 11.27 million N/A N/A
Short Term Investments 20.1 million 20.83 million N/A 9.35 million N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.1 million 720000 N/A 444000 N/A

DiaMedica Therapeutics Inc (DMAC) Chart:

DiaMedica Therapeutics Inc (DMAC) News:

Below you will find a list of latest news for DiaMedica Therapeutics Inc (DMAC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

DiaMedica Therapeutics Inc (DMAC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 00TRUE00
2024-05-1750.05CALL0 43207.15FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-172.50.2PUT0 1088.79FALSE00
2024-05-1750PUT0 0568.34TRUE00
2024-05-177.50PUT0 0340.17TRUE00
2024-06-212.50.2CALL0 270.08TRUE00
2024-06-2150CALL0 00FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50.29PUT0 2085.65FALSE00
2024-06-2150PUT0 0415.44TRUE00
2024-06-217.50PUT0 0224.01TRUE00
2024-07-192.50.25CALL0 2660.76TRUE00
2024-07-1950.05CALL0 880FALSE00
2024-07-197.50.1CALL0 350FALSE00
2024-07-192.50.35PUT0 9491.71FALSE00
2024-07-1951.85PUT0 2205.93TRUE00
2024-07-197.50PUT0 0199.31TRUE00
2024-10-182.50.55CALL0 1391.93TRUE00
2024-10-1850.2CALL0 1138.05FALSE00
2024-10-187.50.1CALL0 3790FALSE00
2024-10-182.50.5PUT0 10106.93FALSE00
2024-10-1850PUT0 0112.48TRUE00
2024-10-187.50PUT0 0220.67TRUE00

Latest DMAC Trades:

Date Shares Price
Jun 13, 2022 3:48 PM EST100$2.29

DiaMedica Therapeutics Inc (DMAC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm
2020-01-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1401040/000000000020000113/0000000000-20-000113-index.htm
2020-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401040/000093583620000089/0000935836-20-000089-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000064/0001235802-19-000064-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000065/0001235802-19-000065-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000066/0001235802-19-000066-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000067/0001235802-19-000067-index.htm
2019-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm
2019-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000130/0001235802-19-000130-index.htm
2019-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580219000131/0001235802-19-000131-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000052/0001235802-20-000052-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000053/0001235802-20-000053-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000054/0001235802-20-000054-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401040/000123580220000055/0001235802-20-000055-index.htm
2020-01-31SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401040/000138713120000815/0001387131-20-000815-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774919016566/0001437749-19-016566-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774919016595/0001437749-19-016595-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774919020938/0001437749-19-020938-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774919022681/0001437749-19-022681-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774919022682/0001437749-19-022682-index.htm
2020-01-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401040/000143774920000070/0001437749-20-000070-index.htm
2020-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920000102/0001437749-20-000102-index.htm
2020-01-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401040/000143774920000296/0001437749-20-000296-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920002238/0001437749-20-002238-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920002240/0001437749-20-002240-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920002327/0001437749-20-002327-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920002598/0001437749-20-002598-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920005905/0001437749-20-005905-index.htm
2020-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1401040/000143774920005906/0001437749-20-005906-index.htm
2020-04-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1401040/000143774920007997/0001437749-20-007997-index.htm
2020-04-20DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1401040/000143774920007998/0001437749-20-007998-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920010597/0001437749-20-010597-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920010599/0001437749-20-010599-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920016682/0001437749-20-016682-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920016685/0001437749-20-016685-index.htm
2020-08-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920017103/0001437749-20-017103-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920017105/0001437749-20-017105-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920017512/0001437749-20-017512-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920017514/0001437749-20-017514-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401040/000143774920022536/0001437749-20-022536-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401040/000143774920022537/0001437749-20-022537-index.htm
2020-01-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1401040/999999999520000060/9999999995-20-000060-index.htm

DiaMedica Therapeutics Inc (DMAC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of DiaMedica Therapeutics Inc (DMAC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 672%
Institutional Ownership: 3931%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-08-19Scott KellenCFO and SecretaryBuy3,000.002.437,290.0010,290.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm
2020-06-01James T. ParsonsDirectorBuy8,102.004.5937,188.1814,202.00https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm
2019-08-16Dietrich John PaulsPresident and CEOBuy1,000.002.682,676.9030,804.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm
2019-08-16Richard D. PilnikDirectorBuy7,840.002.5620,039.0450,678.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm
2020-06-01Richard D. PilnikDirectorBuy10,168.004.5946,671.1260,846.00https://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm
2019-08-16HARRY W JR ALCORNChief Medical OfficerBuy7,260.002.6719,365.328,260.00https://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm
2020-06-01Randall Michael GiuffreDirectorBuy7,784.004.5935,728.5693,588.00https://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm